Ambrose Kristen
SVP & Chief Accounting Officer
Ambrose Kristen has filed 7 SEC Form 4 filings (13 transaction rows) across 1 company, with disclosures dating back to 2026. 7 of those filings fall inside the rolling window. Most recent filing: Sep 1, 2026.
On the most recent filing, Ambrose Kristen is listed as SVP & Chief Accounting Officer at VERTEX PHARMACEUTICALS INC / MA. Inside the rolling window, Ambrose Kristen reported no open-market purchases and 5 open-market sales totaling $2.0M in VRTX. The largest disclosed transaction in the window is a sale of 1,557 VRTX shares on Feb 17, 2026, worth $762K.
Companies traded
Other insiders at VRTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.0M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Ambrose Kristen made?
Ambrose Kristen has filed 7 SEC Form 4 filings (13 transaction rows) across 1 company since 2026.
Which companies does Ambrose Kristen trade?
Ambrose Kristen has filed SEC Form 4 disclosures for 1 company, including VRTX.
When was Ambrose Kristen's most recent SEC Form 4 filing?
Ambrose Kristen's most recent SEC Form 4 filing on Tracefour is dated Sep 1, 2026.
What is Ambrose Kristen's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Ambrose Kristen is listed as SVP & Chief Accounting Officer.
What is Ambrose Kristen's total buy and sell value in the current window?
Inside the rolling retention window, Ambrose Kristen bought $0 and sold $2.0M based on SEC Form 4 filings.
What was Ambrose Kristen's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,557 VRTX shares on 2026-02-17, worth $762K, per SEC Form 4 filings.